Robert F. Kennedy Jr. is backing a primary challenge against two-term Republican Senator Bill Cassidy of Louisiana, directing his political organization against Cassidy after more than a year of reported tensions between the two, according to Bloomberg Politics. The Louisiana race will serve as an early test of whether Kennedy's movement can convert national name recognition into actual primary votes.

Rich Danker, assistant secretary for public affairs at HHS, resigned citing irreconcilable differences with an administration effort to advance flavored e-cigarettes, according to The Hill. Danker left one day after FDA Commissioner Marty Makary moved to expand flavored vape authorizations, which Danker argued risk addicting children.

Health Secretary Robert F. Kennedy Jr.'s initiative to help Americans stop taking antidepressants omits the clinical infrastructure that safe deprescribing requires, including gradual tapering protocols, psychological support, and accessible therapy alternatives, according to STAT News. Said Stanford addiction researcher Keith Humphreys: antidepressants and heroin exist in "different universes" when it comes to addiction risk, directly rebutting Kennedy's public claim — while a 2025 JAMA Psychiatry study found recent gains in psychotherapy access were concentrated almost entirely among younger, wealthier, college-educated, urban adults with private insurance, leaving older, rural, and uninsured patients without the alternatives a deprescribing push would require.

Robert F. Kennedy Jr. has absorbed a series of setbacks at HHS, including Trump's appointment of a vaccine-supporting CDC director, the withdrawal of MAHA ally Casey Means from the surgeon general nomination, and the resignation of FDA Commissioner Marty Makary, according to The Bulwark. Said Kennedy of Trump's replacement surgeon general pick, whom he praised despite her having publicly criticized his efforts to roll back children's vaccine requirements: "I look forward to partnering with her."

Health and Human Services Secretary Robert F. Kennedy Jr. is directing a large-scale vaccine research effort inside the department even as the White House has directed him to soften his public statements on vaccines, according to the New York Times. Kennedy's internal priorities diverge from the public posture the administration has asked him to maintain.

Delayed administration of the hepatitis B vaccine to newborns increases the window of exposure to a virus that can cause chronic liver disease and cancer, according to The Hill. Hepatitis B can be transmitted at birth, and the CDC's Advisory Committee on Immunization Practices recommends the first dose within 24 hours of delivery specifically to close that gap.

The White House is preparing to replace FDA Commissioner Marty Makary, according to the Washington Post, as the agency faces mounting internal turmoil under the broader restructuring driven by Robert F. Kennedy Jr.'s Health and Human Services portfolio.

The play here is transparent: Makary was a Kennedy-adjacent pick meant to legitimize RFK Jr.'s vaccine skepticism inside a credentialed institution. If he's being pushed out now, it means he either wasn't compliant enough or became a liability when the political cost of FDA dysfunction started showing up somewhere that mattered — drug approvals, Wall Street, Republican senators with pharma money.

Watch who replaces him. A more ideologically committed successor signals the administration is doubling down on dismantling FDA's independent scientific posture. A technocrat signals retreat. The nominee is the tell.

Bloomberg Politics reports that Robert F. Kennedy Jr. and a network of personal injury lawyers are pressing a legal campaign against Merck's Gardasil vaccine, accusing the company of 'disease mongering' to inflate sales — a charge that runs directly against decades of mainstream medical consensus on the vaccine's safety and efficacy.

The strategic read: this isn't primarily a tort story. It's an executive-branch play. Kennedy now controls public health infrastructure. Personal injury litigation that once faced an uphill regulatory environment can now proceed in a climate shaped by the very official who built the case against the product.

Who benefits: the plaintiff's bar funding this effort, and an HHS leadership that has spent years treating vaccine approval as a political grievance rather than a public-health process. The constitutional concern is downstream: when a Cabinet officer's ideological priors reshape the regulatory record, every future safety determination at FDA is compromised before it begins.